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Rethinking fatigue in Gaucher disease
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Abstract
Background: Gaucher disease (GD) is a rare lysosomal storage disease caused by deficiency in the enzyme
beta-glucocerebrosidase. Along with visceral, hematologic, and bone manifestations, patients may experience
chronic fatigue resulting in functional disability and reduced quality of life. Management of the disease includes
therapeutic intervention, supportive therapies, and regular monitoring of all clinically relevant disease signs
and symptoms. However, current practice guidelines do not include measurement of fatigue or therapeutic
goals for fatigue.
Objective: To provide insight regarding key considerations for fatigue in GD.
Methods: We conducted a systematic PubMed literature search and an exploratory, hypothesis-generating
survey regarding fatigue in GD.
Results: Our literature search resulted in 19 publications. Of these, 6 were identified that assessed fatigue, including 2
that used specific fatigue assessment instruments. In our survey involving 14 patients with Type 1 GD and 19
physicians, patients ascribed greater importance to fatigue than other disease parameters, while physicians
placed more emphasis on objective measures of visceral and hematologic disease manifestations.
Conclusions: Collectively, the results of our literature analysis and survey underscore the need for further
investigation and in-office evaluation of fatigue in patients with GD, which will require a reliable, validated,
and disease-specific instrument. Criteria for clinically significant fatigue in patients with GD should be established along
with the development of a fatigue scale specifically designed for this patient population to provide a more objective
means to potentially incorporate fatigue assessment into routine monitoring practices.
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Background
Gaucher disease (GD) is the most common lysosomal
storage disorder, with an estimated prevalence of 1
per 57,000 live births in the general population but 1
per 855 in the Ashkenazi Jewish population [1]. It is
an autosomal recessive disorder caused by mutations
in the gene encoding the lysosomal enzyme beta-
glucocerebrosidase (also known as glucosylceramidase
and acid beta-glucosidase; EC 3.2.1.45) [2]. The
resulting enzyme deficiency leads to lysosomal accu-
mulation of the lipid glucocerebroside in macro-
phages, namely Gaucher cells [3, 4]. The phenotypic
expression of GD is highly heterogeneous, and reflects
involvement of various organs [2]. Three types of GD
have been classified based on clinical manifestations.
The most common is Type 1 or non-neuronopathic
GD, which may occur at any age and is common in
the Ashkenazi Jewish population [4]. Anemia,
thrombocytopenia, splenomegaly, hepatomegaly, and
bone involvement, including bone pain, osteoporosis,
joint avascular necrosis, and pathologic fractures, are
common clinical manifestations of GD [4, 5]. Pulmonary
hypertension, cholelithiasis, and autoimmune phenom-
ena may occur in Gaucher patients and the mutations
for Type 1 GD might predispose carriers and patients
with GD to Parkinson disease [2, 6, 7]. Types 2 and 3
GD are acute and chronic neuronopathic forms of the
disease, respectively, which, in addition to variable de-
grees of visceral involvement, have progressive central
nervous system manifestations [2].
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Management of GD includes enzyme replacement
therapy (ERT), substrate inhibitors, and supportive
therapies [8–10]. Regular monitoring of all clinically
relevant disease signs and symptoms [8, 9] and la-
boratory parameters is essential. Practice guidelines
provide consensus recommendations for the manage-
ment of patients with Type 1 GD; guidelines vary ac-
cording to patient clinical status and achievement of
therapeutic goals [9]. To optimize outcomes, clinically
relevant aspects of disease should be evaluated at
regular intervals, including complete physical examin-
ation; measurements of hemoglobin concentration,
platelet count, and disease-related biomarkers; and
radiologic imaging to assess liver and spleen volumes
and skeletal involvement [9]. Evaluation of patient-
reported quality of life is also recommended using the
36-item Short Form Health Survey (SF-36) [9].
Patients with GD may also experience chronic fa-
tigue that causes functional disability and adversely
affects quality of life [11]. Objective disease manifesta-
tions such as anemia and bone pain can cause or
contribute to fatigue [8]. For some patients, fatigue
may be the most debilitating symptom of the disease
[11]. Practice guidelines for patients with GD do not
currently include specific measurements of fatigue [9];
moreover, management of fatigue per se is not in-
cluded in established therapeutic goals, although re-
ducing fatigue is mentioned under therapeutic goals
for anemia in patients with GD [8].
The objectives of this review are to examine fatigue
as a core GD symptom and determine how fatigue in
GD has been measured in the medical literature
through a systematic literature search and analysis
and to provide preliminary information on the im-
portance ascribed to fatigue by physicians and pa-
tients through an exploratory, hypothesis-generating
survey of physicians and patients.
Methods
Assessment of fatigue in the published literature
We conducted PubMed searches to identify studies in
which fatigue was assessed in patients with GD. Publica-
tions were identified using “Gaucher disease” as a text
term and limiting the results to clinical trial papers pub-
lished from January 1991 through March 4, 2016. The
term “fatigue” was added to restrict articles to those of
interest on this topic.
Physician and patient surveys on the importance of fatigue
Following institutional review board (IRB) approval
(0139–14; signed consent forms were not required by
the IRB as survey responses were considered to be con-
sent), we conducted a survey of 25 patients with GD and
25 physicians with experience in treating patients with
GD from multiple institutions worldwide. Patients
were recruited consecutively from the Gaucher clinic
in the hematology department of the Rambam Health
Care Campus in Haifa, Israel, where approximately
160 patients were followed at the time the survey was
conducted. Physicians and patients were approached
via e-mail and responded via e-mail. Patient records
were not included or evaluated. Physicians and pa-
tients were asked to rate the importance of 6 parame-
ters using a Likert scale ranging from 1 to 9, with 9
assigning the highest importance [12]. The parameters
included fatigue as well as 5 commonly monitored
parameters affected by GD: 1) Complete blood count
(CBC; including hemoglobin concentration and platelet
count); 2) Liver and spleen volume; 3) Disease-related bio-
markers; 4) Bone density; and 5) Bone pain.
Results
Assessment of fatigue in the published literature
Our searches resulted in 19 publications (Table 1).
Fifteen manuscripts were published in English [11, 13–26],
and the remaining 4 articles were published in German
[27], French [28], Hungarian [29], and Danish [30]. For the
articles published in German, French, Hungarian, or Da-
nish, English-language abstracts were available and
reviewed. Full-text articles were reviewed for those
published in English.
None of the identified studies evaluated fatigue as a
primary end point, but 2 studies used a standard
assessment tool for fatigue. Samuels and colleagues
[22] used the Functional Assessment of Chronic Ill-
ness Therapy-Fatigue (FACIT-F; www.facit.org/FACITOrg/
Questionnaires) questionnaire to evaluate fatigue in a cohort
of 12 patients receiving acupuncture for GD symptoms,
which included bone/joint pain, headache, or fatigue.
FACIT-F version 4 comprises 27 general items within 4
domains (physical well-being, social/family well-being,
emotional well-being, and functional well-being) and 13
“additional concerns” related to fatigue. Each item is
scored on a 5-point Likert scale, with scores ranging
from 0 (not at all) to 4 (very much). After receiving
acupuncture, patients experienced significant improve-
ment in the FACIT-F physical well-being subscale [22].
Fatigue was among the symptoms evaluated in adults
with GD who participated in the National Collaborative
Study of Lysosomal Storage Disorders (NCS-LSD), a
longitudinal, cohort study of patients who are receiving
treatment at 7 designated centers in England [23]. This
study was designed to determine the natural history of
the lysosomal storage diseases under investigation, in-
cluding GD, and to estimate clinical effectiveness and
cost-effectiveness of treatment strategies. In this study,
fatigue was assessed using the Fatigue Severity Scale
(FSS) and was included, in addition to other quality-of-
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life measures, because patient support groups have con-
sidered fatigue to be a key feature of the disease [23].
The FSS is a 9-item tool; each item is scored on a scale
from 1 to 7 [31], with a mean score of 4 or higher con-
sidered to represent significant fatigue [23]. The study
cohort completed 134 FSS questionnaires; all patients
Table 1 Articles identified from PubMed literature search using terms “Gaucher Disease” and “Fatigue”
Reference Language Patients (N) Fatigue assessed? Fatigue tool Data description
Verderese et al., 1993 [13] English 12 Yes 5 questions All patients reported chronic fatigue as a pervasive
problem at baseline; all perceived improvement at
4 months after starting ERT
Niederau et al., 1994 [14] English 5 Yes None mentioned Case reports of 5 patients with GD receiving ERT for
12–18 months; all reported marked reductions in
fatigue within a few weeks after starting ERT
Gagnon et al., 1998 [15] English 24 Yes Questionnaire;
fatigue either
yes/no
National Gaucher Foundation GD screening program;
fatigue was the most commonly reported symptom
(79.4 % of all respondents; only 24 patients had
confirmed GD)
Hayes et al., 1998 [11] English 16 Yes Unspecified Patients asked open-ended questions about chronic
fatigue which were based on components of several
unspecified instruments; 88 % reported being easily
fatigued
Niederau et al., 1998 [16] English 1 Yes None mentioned Case report of elderly patient with GD receiving ERT
for 30 months; fatigue decreased within several
months of starting ERT
Masek et al., 1999 [17] English 25 Yes SF-36 SF-36 administered before and after initiation of ERT;
vitality domain (a measure of energy and fatigue) was
improved significantly at 6, 12, 18, and 24 months vs.
pretherapy
Khan et al., 2000 [18] English 1 Yes None mentioned Case report of diagnosis of adolescent patient with
GD; fatigue mentioned as a presenting and persisting
symptom
Chou et al., 2004 [19] English 1 No — Case report of diagnosis of adolescent patient with GD
Tsai et al., 2008 [20] English 7 Muscle fatigue
only
— Evaluation of myopathy in GD; 3 patients developed
insidious, nonprogressive muscle weakness with easy
muscle fatigue; other measures of fatigue not assessed
Shapiro et al., 2009 [21] English — — — Describes clinical trial in patients with Tay-Sachs
disease; not relevant to analysis of fatigue in GD
Samuels et al., 2012 [22] English 12 Yes FACIT-F “Additional concerns” of fatigue evaluated at baseline
and following acupuncture treatment; mean scores
on fatigue-specific scale of FACIT-F increased following
acupuncture (27.6 vs. 35.9; P = 0.008)
Wyatt et al., 2012 [23] English 134 Yes FSS All patients receiving ERT; no longitudinal data; found
no association between fatigue and time on ERT (P= 0.57)
Elstein et al., 2015 [24] English 38 No None Patients received velaglucerase alfa in an extension
trial; reports of fatigue were collected as adverse
events and as infusion-associated reactions
Stirnemann et al., 2015 [25] English 99 Yes None mentioned Retrospective collection of data on patients’
characteristics, treatment, and clinical and biological
parameters; fatigue was reported in 8 % of patients
Dulgar et al., 2016 [26] English 1 Yes None mentioned Case report of 1 patient with tuberculosis and
untreated GD; fatigue mentioned as symptom
Niederau et al., 2001 [27] German — Unknown Unknown German recommendations for diagnosis and treatment
of GD; fatigue mentioned as common symptom
Schaison et al., 2002 [28] French 108 Yes Unknown Fatigue alleviated by ERT
Juhász et al., 2012 [29] Hungarian 2 Unknown — Case report of 2 patients diagnosed in late adulthood;
fatigue mentioned as GD sign/symptom
Hansen et al., 2015 [30] Danish 1 Yes Unknown Case report of a 10-year-old girl with GD; extreme
fatigue over several years was reported
ERT enzyme-replacement therapy, FACIT-F Functional Assessment of Chronic Illness Therapy–Fatigue, FSS Fatigue Severity Scale, GD Gaucher disease, SF-36 36-item
Short Form Health Survey
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were receiving ERT. In exploratory modeling, no associ-
ation was identified between fatigue and time on ERT
(P = 0.57); a further longitudinal analysis was not con-
ducted and no data were available for patients who did
not receive ERT [23].
The other publications did not use a validated fatigue-
specific instrument, as described below. Hayes et al. [11]
interviewed 16 patients about chronic fatigue and other
symptoms. Of these, 13 patients had been receiving ERT
for 6 months or longer. To measure fatigue, the authors
developed open-ended questions based on several
quality-of-life instruments [11]. Overall, 14 patients
(88 %) reported being easily fatigued and 8 patients
(50 %) mentioned sleeping many hours or needing naps
[11]. Four patients (25 %) reported that, in addition to
other challenges due to GD, dealing with bone pain or
fatigue was the most difficult aspect of their disease.
Masek and colleagues [17] evaluated the effect of ERT
on health-related quality of life in 25 adult patients. A
fatigue-specific assessment tool was not used; instead,
the SF-36 questionnaire was administered at baseline
and then every 6 months after starting ERT. SF-36 in-
cludes a domain for vitality, which encompasses energy
and fatigue. The benefit of ERT was most evident on the
vitality, role-physical, and social functioning domains.
Notably, vitality was the first domain to show significant
improvement after starting ERT, an effect that was noted
at 6 months and maintained through the end of the
24-month study.
Verderese et al. [13] conducted a pilot study to evalu-
ate the effects of ERT on symptoms associated with GD.
Patients completed a self-assessment questionnaire in
which they were asked to comment about the presence
or absence of symptoms, including 5 questions related
to chronic fatigue. All of the 12 patients included in the
study reported pervasive chronic fatigue at baseline, and
all perceived improvement in fatigue at 4 months after
starting ERT. However, the level of improvement in
chronic fatigue varied considerably among patients. In
an article published in French, Schaison and colleagues
[28] reported that fatigue was alleviated by ERT in 108
patients with severe Type 1 GD. In an early GD screen-
ing program of the US National Gaucher Foundation, fa-
tigue was assessed as a yes/no checkbox in a brief
screening interview questionnaire [15]. Fatigue was the
most commonly reported symptom and was reported by
79 % of respondents [15].
Other publications that mentioned fatigue as a symp-
tom were case reports [14, 16, 18, 26, 30] and a study
that evaluated muscle fatigue but did not evaluate more
general concerns regarding fatigue [20]. Elstein et al.
[24] reported long-term safety findings in 38 patients
from an extension study of a phase II/III trial in which
patients with GD switched treatment from imiglucerase
to velaglucerase alfa. Fatigue was reported as an adverse
event possibly or probably related to velaglucerase alfa
treatment and as an infusion-associated reaction in 2 pa-
tients [24]. In an observational retrospective study of 99
French patients with GD, data regarding demographics,
GD history, treatment, and biological and clinical char-
acteristics were collected; other GD-related data could
also be spontaneously reported by the investigators [25].
Fatigue was the most frequently reported GD-related
event (8 %); no mention was made of any formal tools
used to assess fatigue [25].
Physician and patient surveys on the importance of fatigue
Nineteen physicians responded and had a median of
28 years of experience in treating this patient popula-
tion. They represented several different specialties,
most frequently hematology, internal medicine, and
pediatrics. Eighteen physicians (95 %) worked at an
academic teaching hospital and/or specialist referral
center in Spain, Brazil, France, Israel, Mexico, the
United Kingdom, Australia, Canada, Chile, Italy,
Poland, or Serbia. Fourteen patients responded; all
were over the age of 18 years. The patients had been
diagnosed with GD for a median of 15.5 years (range:
4–48 years). No matching of physicians with patients
took place.
The physicians’ mean scores for the importance of
each physical GD manifestation and fatigue were as
follows: CBC, 8.2; bone pain, 8.0; liver/spleen volume,
7.4; bone density, 6.9; biomarkers, 6.4; and fatigue,
5.8. We also sought to understand how many physi-
cians assessed fatigue during patient visits. Overall, 10
physicians (53 %) reported that they evaluated fatigue
in their patients. Three indicated that they used the
SF-36 questionnaire to measure fatigue, whereas the
others used a variety of methods, including direct
questioning, descriptive terms, quantitative history, or
subjective patient self-report. One physician used a
subjective 1–10 scale during direct questioning and
another used the fatigue assessment tool from the
Fabry Registry. The patients’ mean scores for the im-
portance of each physical manifestation and fatigue
were as follows: fatigue, 7.6; bone pain, 7.3; liver/
spleen volume, 6.4; bone density, 6.2, biomarkers, 4.8;
and CBC, 4.0.
Discussion
The results of our literature search and analysis indi-
cated that there is limited peer-reviewed information on
the topic of fatigue in patients with GD and suggests
that there is a need for more information on this topic.
In an effort to shed light on the issue of fatigue in GD,
we conducted an exploratory, hypothesis-generating
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survey to provide preliminary information on the im-
portance ascribed to fatigue by physicians and patients.
The measurement of fatigue using standard, validated
instruments is common in many chronic illnesses, in-
cluding cancer, chronic inflammatory diseases, depres-
sion, human immunodeficiency virus, and stroke, but
generally not in GD [32–34]. The results of our litera-
ture review support fatigue as a core symptom in pa-
tients with Type 1 GD. Moreover, our survey of
patients with Type 1 GD, albeit limited in size, illus-
trates the importance ascribed by patients to fatigue.
Since publication of the pivotal trial for the first ERT
for GD in 1991 [35], nearly 3,000 articles on GD were
published through December 2014, including approxi-
mately 100 clinical trials. From this body of literature,
we identified 6 articles that assessed fatigue and only 2
articles that used a fatigue-specific instrument. These
findings illustrate a gap in the medical literature regard-
ing assessment of fatigue in patients with GD.
The limitations of our survey include a small sample
size and lack of testing/objective determination on
whether the patients surveyed are representative of
patients with GD in general. It should be noted that pa-
tients with GD experience a wide range of other condi-
tions that may also contribute to fatigue and might
explain why they ascribe high importance to fatigue.
Recognizing these inherent limitations, including those
of comparing scores between the small groups of physi-
cians and patients, it is interesting to note that patients
ascribed greater importance to fatigue than did physi-
cians (7.6 vs. 5.8), whereas the physicians ascribed
greater importance to testing of hemoglobin/platelet
counts than did patients (8.2 vs. 4.0). This apparent
discrepancy between physician versus patient scores may
be due to several factors. First, there are correctable fac-
tors that can cause fatigue, such as anemia [8]; such fac-
tors should be explored when a patient has fatigue. The
fact that anemia is both correctable and can be mea-
sured objectively may be why physicians place higher
importance on this GD manifestation than fatigue, for
which there are no objective measures and no clear clin-
ical evidence that supports treatment in GD. The sever-
ity and/or seriousness of other disease parameters, such
as platelet count, spleen volume, liver volume, and bone
manifestations, may lead physicians to prioritize these
symptoms, especially because ERT improves them [8].
To patients, fatigue may be one of the most important
disease aspects of GD because physicians have become
adept at managing the other disease manifestations,
which are therefore less problematic for patients. Finally,
physicians may be likely to consider objective measures
of disease to be most important, whereas patients may
be likely to place greater emphasis on less objective fac-
tors that may affect their daily living. The availability of
a better assessment instrument for fatigue may provide
physicians with a more objective measure and possibly
lead to increased evaluation of this important disease
manifestation.
The available literature suggests that patients with
GD have improvements in fatigue within 6 months of
starting ERT, and that it may be among the first
symptoms to show significant improvement [11, 13, 17].
However, this belief is based largely on anecdotal evidence
and requires clinical trial evidence using fatigue-specific
instruments validated for use in patients with GD. Infor-
mation from patients with other lysosomal storage dis-
eases indicates that fatigue is also problematic in those
patients and may improve with the introduction of ERT.
For example, in 2 studies, meaningful improvements
in fatigue assessed with the FSS were seen shortly
after introduction of ERT in some patients with
Pompe disease [36, 37]. Moreover, successful treat-
ment of fatigue has been an important outcome in
numerous chronic illnesses, including cancer, systemic
lupus erythematosus, and multiple sclerosis [38–40].
The measurement of fatigue is challenging because of
the lack of a standard definition as well as its subjective
and nonspecific nature. Patients with fatigue typically
have difficulty starting or maintaining voluntary activ-
ities and may experience feelings of tiredness, lack of en-
ergy, and exhaustion [34, 41]. Fatigue is a complex
interaction between a disease process and factors such
as muscle fatigue, self-perceived feelings of fatigue, and
the individual’s environment [34, 41]. To address these
issues, fatigue assessment instruments must be easy for
individuals to understand and complete, must be capable
of measuring the impact of therapeutic interventions,
and have robust psychometric properties (Table 2) [42].
Table 2 Characteristics of an ideal fatigue assessment tool
(Adapted from Whitehead, 2009 [42])
Parameter Ideal tool
Scale usability • Easy to understand and complete
• Minimal burden for patient and physician
Clinical utility • Discriminates presence versus absence of fatigue
with acceptable sensitivity and specificity
• Provides description of severity of fatigue and its
impact
• Useful as outcome measure sensitive to changes
with disease worsening or therapeutic intervention
Psychometric
properties
• Robust precision and accuracy
• Reliable and consistent with good reproducibility
• Stable and repeatable over time and among raters
• Possesses stable structure that measures what is
intended
• Correlates reasonably with similar fatigue-specific
tools
• Discriminates between different patient groups
and symptoms
• Captures change in fatigue symptoms over time
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The literature review and surveys described herein
underscore the need for a validated scale to measure fa-
tigue in patients with GD. As evident from the results of
the literature search and survey, fatigue can be an import-
ant factor when evaluating and treating patients with GD.
The absence of practice guidelines for the measurement of
fatigue in GD may discourage healthcare providers from
measuring this domain before treatment and incorporating
it as an important treatment goal. Without an empirically
generated, validated, and reliable tool, it is problematic to
accurately and appropriately measure fatigue as a core
symptom in patients with GD. The tool should be disease
specific, age appropriate, culturally appropriate, and sensi-
tive for detecting changes that are clinically meaningful for
patients. The tool will need to be adapted for different age
groups given that perceptions of fatigue and the effects of
fatigue may vary. As no existing tool fully meets the needs
of assessing fatigue in patients with GD, a new tool may
need to be developed and compared with results obtained
using existing tool(s).
Several questions remain unanswered regarding fatigue
in patients with Type 1 GD. First, the etiology of fatigue in
patients with GD is not clear. In addition to correctable
symptoms such as anemia [8], multiple factors are known
to contribute to fatigue, including pain, depression, anx-
iety, sleep disturbances, emotional distress, activity level,
and medication side effects [38]. Fatigue in GD may also
be a manifestation of other disease-related events, includ-
ing elevated plasma cytokine levels [43], hypermetabolism
[44], or myopathy [20]. Second, correlations of fatigue
with other signs and symptoms of GD, such as anemia
and bone pain, require clarification. Finally, identification
of optimal treatment modalities for addressing fatigue in
patients with GD remains to be defined, and may be facili-
tated by the creation of a validated and specific tool to
measure fatigue in patients with GD.
Conclusion
In summary, patients with Type 1 GD report that fa-
tigue substantially impairs quality of life and social
functioning, and may be a debilitating symptom of
their disease. However, validated, specific tools for
clinical assessment of fatigue in patients with GD are
not available and constitute a significant unmet need.
We propose an expert consensus project to establish
criteria for clinically significant fatigue in patients
with GD and the development of a validated and spe-
cific fatigue scale for patients with GD.
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